Portfolio companies news

15 August 2016

NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women with Recurrent Vulvovaginal Candidiasis (RVVC)

NovaDigm Therapeutics, a company developing innovative immunotherapeutics and preventative vaccines for fungal and bacterial infections, today announced positive data from the Company’s Phase 2a clinical trial evaluating its NDV-3A immunotherapeutic vaccine in women with recurrent vulvovaginal candidiasis (RVVC). Initial results were presented at the Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology in Annapolis, Maryland on August 13, 2016 by Paul Nyirjesy, MD, Professor of Obstetrics and Gynecology and of Medicine at Drexel University College of Medicine.

11 August 2016

Clearside Biomedical, Inc. Reports Second Quarter 2016 Financial Results

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reported a corporate update and financial results for the quarter ended  June 30, 2016 .

11 August 2016

Miramar Labs, Inc. ® Reports Record Second Quarter 2016 Financial Results

Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today financial results for the second quarter ended June 30, 2016: Second quarter revenue of $7.4 million, up 47% year-over-year, year-to-date revenue of $11.7 million, up 46% year-over-year, shipped record number of miraDry® systems and consumables in the second quarter

11 August 2016

Neothetics Provides Business Update and Reports Second Quarter 2016 Financial Results

Neothetics, Inc.  (NASDAQ:NEOT) today provided a business update on its strategic and operational initiatives and reported financial results for the second quarter 2016.

10 August 2016

ReVision Optics Names Dr. Nick J. Manesis Vice President of R&D

ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces the appointment of Nick J. Manesis, PhD as Vice President of R&D. Dr. Manesis brings to RVO nearly 30 years of materials research and development experience, including at the leading ophthalmic companies Allergan and CooperVision.

09 August 2016

Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update

 Syndax Pharmaceuticals (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the second quarter ended June 30, 2016 and provided a pipeline update as well as a review of upcoming milestones.  As of June 30, 2016, Syndax had $125.5 million in cash, cash equivalents and short-term investments.

09 August 2016

Tobira Therapeutics Reports Second Quarter 2016 Financial and Business Results

Tobira Therapeutics, Inc.  ( NASDAQ : TBRA) a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today reported business highlights and financial results for the three months ended  June 30, 2016 .

09 August 2016

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2016 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and announced its financial results for the second quarter ended June 30, 2016.

03 August 2016

Miramar Labs’ miraDry System Featured in Cover Story in The Aesthetic Guide

Miramar Labs, Inc., (OTCQB: MRLB), a global aesthetic company, announced today that the Company’s miraDry^® system is featured in a cover story in the July/August edition of The Aesthetic Guide. The miraDry system delivers microwave energy to non-invasively destroy sweat and odor glands in the underarm, and is also approved for permanent hair removal of the underarm. The cover story article, titled “Miramar Labs Creates New Markets with miraWave Therapy,” may be accessed on-line in the current issue of the magazine.

01 August 2016

Study Shows Corneal Structural Changes Induced by ReVision Optics’ Raindrop® Near Vision Inlay Significantly Improve Near and Intermediate Vision in Subjects with Presbyopia

ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces clinical results indicating that structural changes induced by the corneal shape-changing Raindrop Near Vision Inlay leads to significantly improved near and intermediate vision in subjects with presbyopia, with no loss of distance binocular acuity.